Oncology · Medical Literature
Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial.
Abstract
Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter randomized controlled trial, 48 patients with TIPN were randomized into three groups: acupuncture (n=16), press-tack needle (n=17), and wait-list control (n=15). The acupuncture group received 12 sessions of manual and electroacupuncture (2 Hz) over 13 weeks. The press-tack needle group applied "PYONEX Zero" to specific acupoints daily. The primary outcome was the change in the Visual Analogue Scale (VAS) score for numbness from baseline to week 13. Secondary outcomes included patient-reported outcome common terminology criteria for adverse events (PRO-CTCAE), the Functional Assessment of Cancer Therapy-Taxane neurotoxicity subscale (FACT-Tns), and analgesic medication costs. No statistically significant difference was observed in the primary VAS endpoint between the acupuncture and control groups (p=0.6023). However, PRO-CTCAE scores revealed that the acupuncture group experienced significantly lower interference from numbness/tingling (p=0.0173) and pain (p=0.0186) than the waiting-list control. For numbness/tingling, the acupuncture group also significantly outperformed the press-tack needle group (p=0.0429). Additionally, the acupuncture group demonstrated significantly better FACT-Tns scores compared to the press-tack needle group (p=0.0333). Analgesic costs remained unchanged across all groups. Adverse events were few and mild. Although underpowered to detect differences in the primary outcome, secondary analyses suggest that professional acupuncture may mitigate the functional interference of TIPN and improve neurotoxicity-specific quality of life.
Clinical relevance
Taxane-induced peripheral neuropathy (TIPN) is a prevalent and often dose-limiting toxicity in oncology patients receiving taxane-based chemotherapy, with no well-established pharmacologic treatment. This multicenter RCT addresses the critical gap in non-pharmacologic management strategies for TIPN, a condition that substantially impairs quality of life and functional status in a broad cancer population. Given the lack of effective standard interventions, these findings are timely and relevant for oncologists and integrative medicine specialists seeking adjunctive symptom management options.
Key findings
1. No statistically significant difference was observed in the primary endpoint — VAS score for numbness from baseline to week 13 — between the acupuncture group and the wait-list control (p=0.6023), though the trial was likely underpowered (n=48 total; acupuncture n=16, press-tack n=17, control n=15). 2. PRO-CTCAE scores demonstrated that the acupuncture group experienced significantly lower functional interference from numbness/tingling compared to the wait-list control (p=0.0173). 3. PRO-CTCAE scores also showed significantly lower pain interference in the acupuncture group versus the wait-list control (p=0.0186). 4. The acupuncture group significantly outperformed the press-tack needle group on the PRO-CTCAE numbness/tingling interference subscale (p=0.0429), suggesting that professional acupuncture confers benefits beyond sham or self-administered needling. 5. The acupuncture group demonstrated significantly better FACT-Tns (Functional Assessment of Cancer Therapy-Taxane neurotoxicity subscale) scores compared to the press-tack needle group (p=0.0333), indicating improved neurotoxicity-specific quality of life. 6. Analgesic medication costs remained unchanged across all three groups, and adverse events were few and mild, supporting the safety profile of both acupuncture modalities.
Practice implications
Professional acupuncture — delivered as 12 sessions of manual and electroacupuncture (2 Hz) over 13 weeks — may be considered as an adjunctive intervention for cancer patients experiencing functional impairment and reduced quality of life due to TIPN, particularly when pharmacologic options are inadequate or poorly tolerated. Self-administered press-tack needles (e.g., PYONEX Zero) did not demonstrate equivalent benefit to professional acupuncture in secondary outcomes, suggesting that provider-administered treatment is preferable and that patient-directed acupoint devices should not be considered a substitute. Clinicians should interpret these findings cautiously given the small sample size, lack of statistical significance on the primary VAS endpoint, and inherent difficulty in blinding acupuncture trials, and should advocate for adequately powered confirmatory RCTs before widespread adoption.